<DOC>
	<DOCNO>NCT01437397</DOCNO>
	<brief_summary>The purpose Phase III study ass maintenance bronchodilator effect fix dose combination versus monotherapies . This study also assess effect fix dose combination term COPD symptom , disease relate health status long-term safety tolerability fix dose combination . This study include 24 week treatment period , precede run-in period , follow two week follow visit . All patient randomize one four treatment arm placebo .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide Formoterol Fumarate Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Male female patient least 40 year age Current former cigarette smoker cigarette smoke history least 10 packyears A diagnosis stable moderate severe COPD stable airway obstruction define GOLD guideline stable airway obstruction . Patients postbronchodilator FEV1/FVC ratio &lt; 70 % Visit 1 ( GOLD , 2010 ) Postalbuterol/salbutamol FEV1 value ≥ 30 % &lt; 80 % predict value . FEV1 measure Screening Visit ( Visit 1 ) 10 15 minute inhalation albuterol/salbutamol . Predicted normal used calculation purpose base National Health Nutrition Examination Survey III predict value ( Hankinson et al , 1999 ) Able perform acceptable repeatable pulmonary function test FEV1 accord ATS/ERS criterion ( Miller et al , 2005 ) Screening Visit ( Visit 1 ) throughout participation trial Negative serum βhuman chorionic gonadotropin pregnancy test Visit 1 must use hormonal contraceptive barrier method plus spermicidal agent ; otherwise least 1year postmenopausal surgically sterile , defined hysterectomy tubal ligation ( applied female patient ) Judged Principal Investigator otherwise good stable health base medical history , physical examination , ECGs , routine laboratory data evaluation Patients previously randomize aclidinium monotherapy trial permit long least 6 month since completion previous trial participation Able understand study procedure willing participate study indicate sign informed consent Hospitalization acute COPD exacerbation within 3 month Visit 1 Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation 6 week Visit 1 . Patients develop respiratory tract infection COPD exacerbation washout runin period discontinue study randomization Any clinically significant respiratory condition COPD , include active tuberculosis , history interstitial lung disease , pulmonary thromboembolic disease , history α1antitrypsin deficiency , pulmonary resection , lung volume surgery , thoracic surgery past 12 month , history bronchiectasis secondary respiratory disease COPD ( eg , cystic fibrosis , Kartagener syndrome ) , post organ transplantation , expect require thoracotomy lung surgery study Clinical history suggest patient asthma oppose COPD ( Study Physician contact discuss eligibility , necessary ) Chronic use oxygen therapy ≥ 15 hours/day Body mass index ( BMI ) ≥ 40 kg/m2 Patients intend start pulmonary rehabilitation program trial exclude , well finish start within 3 month prior Screening Visit Clinically significant cardiovascular condition include : myocardial infarction within previous 6 month ; newly diagnose arrhythmia within previous 3 month ; unstable angina ; unstable arrhythmia require change pharmacological therapy intervention within previous 6 month ; presence automate implantable cardioverterdefibrillator ; history thoracic surgery within past year screening ; hospitalization within previous 12 month heart failure New York Heart Association functional class III ( mark limitation physical activity comfortable rest , less ordinary activity cause fatigue , palpitation dyspnea ) , class IV ( unable carry physical activity without discomfort ) ( Criteria Committee New York Heart Association criterion , 1994 ) Any uncontrolled infection may place patient risk result human immunodeficiency virus , active hepatitis and/or patient diagnose active tuberculosis QTcB &gt; 470 msec rest ECGs perform Screening ( Visit 1 ) , indicate centralized ECG vendor generate report . Patients stable dose medication may prolong QTc , document , stable , normal QTc , could consider QTcB &gt; 470 msec rest ECGs perform randomization Visit 2 , indicate paper tracing generate Sponsorprovided ECG equipment Clinically relevant abnormality result clinical laboratory test , ECG parameter QTc , physical examination vital sign Visit 1 except related COPD History drug alcohol abuse within previous 5 year Any serious uncontrolled physical mental condition/disease , judge Investigator , could place patient high risk derive his/her participation study , could confound result study , would likely prevent patient comply requirement study complete study . If history disease , condition stable 1 year judge Investigator interfere patient 's participation study , patient may include , document approval Study Physician History hypersensitivity reaction inhale anticholinergic , beta2 agonist , sympathomimetic amine , inhaled medication component thereof ( include report paradoxical bronchospasm ) history acute urinary retention , symptomatic benign prostatic hyperplasia , bladder neck obstruction , narrowangle glaucoma . ( Note : Patients well control , stable , asymptomatic benign prostatic hyperplasia exclude ) Sitting , rest systolic BP ≥ 160 mm Hg and/or diastolic BP ≥ 100 mm Hg Visit 1 Visit 2 Unable use multidose drypowder inhaler pressurize metereddose inhaler Treatment investigational product within 30 day ( 6 halflives , whichever long ) Visit 1 Previous participation clinical trial aclidinium bromide FDC therapy Pregnant breastfeeding Current diagnosis cancer ( present patient ) basal squamous cell skin cancer . Patients history cancer must clear Visit 1 ( Screening ) casebycase basis Patients maintain regular day/night , waking/sleeping cycle ( eg , night shift worker ) Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication ( Appendix III protocol , find Appendix 16.1.1 report ) Patients unlikely compliant study requirement ( eg , take medication , complete electronic diary , attend clinic require time ) Patients employee relative employee investigative study center , FRI , Almirall , SA , Pharmaceutical Product Development ( PPD , Inc. ) Patients condition , Investigator 's opinion , might indicate patient unsuitable study support exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
</DOC>